RNAi agents modified at the 4′-C position
US10119136B2 · kind B2 · utility
3Cited by
0References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 9, 2015 |
| Grant date | Nov 6, 2018 |
| Priority date | — |
| Expiry date | Jan 9, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/53
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
One aspect of the present invention relates to double-stranded RNAi (dsRNA) duplex agent capable of inhibiting the expression of a target gene in vivo. The dsRNA duplex comprises one or more 4′-modifications in one or both strand. Other aspects of the invention relates to pharmaceutical compositions comprising these dsRNA agents suitable for in vivo therapeutic use, and methods of inhibiting the expression of a target gene by administering these dsRNA agents, e.g., for the treatment of various disease conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.